Explore Beta Thalassemia, Gene Therapy and more!

Explore related topics

Gene therapy developer bluebird bio (BLUE), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LentiGlobin, its drug product for the treatment of transfusion-dependent patients with beta-thalassemia major.

bluebird bios Rare Blood Disorder Drug Tagged a Breakthrough by the FDA

#Sanofi Job Cuts Backed by French Minister - http://news.clinicalprofessionals.co.uk/?p=2281# #pharma

Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions

The rising cost of cancer drugs is having an impact on treatment decisions - pharma needs a rethink.

Analysis: Drug costs become bigger issue in cancer care

In the past, money was no object when cancer specialists considered which drugs would provide the best treatment for their patients.

New biologic treatment for hypoparathyroidism Rare endocrine disorder affects calcium production

Food and Drug Administration today approved Natpara (parathyroid horomone) to control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism, a rare disease that affects approximately people in the United States.

Thinking About Starting a Home-Based Business? - U.S Small Business Administration; covers many answers.

Great resources for small business advice: Is entrepreneurship for you, 20 questions before starting, 10 steps to starting a business, writing a business plan and more SBA.GOV site - U.S Small Business Administration

FDA Approves New Long Acting Painkiller

Dikkat Eksikliği Tanısı – Objektif Nöro Analiz - Brain Center of İstanbul

sandoz_logo.jpg (JPEG Image, 1183 × 329 pixels)

sandoz_logo.jpg (JPEG Image, 1183 × 329 pixels)

NICE Grants Regulatory Approval for Expanded Use of Efient

NICE Draft Guidance Backs Hepatitis C Drug - Clinical Professionals

Takeda

Takeda Pharmaceutical, Major Drug Company, Plans to Leave Bay Area

Facebook introduces Messenger Platform with e-commerce component. NEW YORK (MarketWatch) - Facebook Inc. FB, +0.22% launched Messenger Platform on Wednesday at the company's annual developer conference to allow developers to build apps and functions within the traditional Facebook Messenger app. http://on.mktw.net/19mFOAW

Workday Announces Date of Fiscal 2015 Fourth Quarter and Full Year Financial Results

Pinterest
Search